DailyIQ
Last updated 100 days ago

ALNY·ALNY

$.
+. (+.%)
After Hours
High
$318.44
Open
$301.88
Market Cap
41.54B
52W High
$495.55
Low
$301.17
P. Close
$308.48
P/E
953.44
52W Low
$205.87
Fwd P/E
-
Mean Target
-
Technical Score (1D)
32
SELL
News Sentiment
61
BULLISH
Recent analyst actions and earnings results are shaping the outlook for Alnylam. Several analysts have recently adjusted price targets, with Bank of America and H.C. Wainwright lowering theirs, while Barclays initiated coverage with an Overweight rating. This mixed sentiment reflects evolving expectations for the company's performance. Alnylam's Q4 earnings beat estimates, but revenue missed despite significant year-over-year growth, primarily driven by Amvuttra. This mixed financial performance has led to investor concern. The stock has experienced recent declines, prompting reassessments of its valuation. Market reactions to clinical and regulatory milestones are key drivers of price movements. The TTR market dynamics and management's long-term spending plans are also key concerns for investors. Early-stage clinical data readouts could provide potential catalysts for the stock. Analysts' opinions vary, with an average 12-month price target of $471.54. Investors should watch for further analyst revisions and updates on clinical trial progress.
Earnings Summary
Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference, operating within the healthcare sector. The company's product portfolio includes treatments for various conditions, such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria. Recent quarterly performance shows a mixed trend, with Q4 2024 reporting an EPS of $0.06, beating the estimate of -$0.14, and revenue of $593.16 million. However, Q4 2025 saw an EPS of $1.25, missing the estimate of $2.21, and revenue of $1.1 billion, also missing the estimate of $1.14 billion. The company beat estimates in one of the last two quarters. Alnylam's revenue growth has been substantial, driven by its TTR franchise and Amvuttra, but the company's earnings trajectory is inconsistent. Recent news indicates that Alnylam's Q4 earnings beat estimates, but revenue missed, leading to investor concern. The company is also advancing its pipeline, with data readouts expected in the second half of 2026. Investors should watch for further analyst revisions and updates on clinical trial progress, as well as the company's ability to meet its ambitious growth targets.

EPS

EstBeatMiss
$-0.49$0.27$1.03$1.80$2.56Q4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$0.95$1.99+108.9%
Q4'25$2.21$1.25-43.4%
Q4'24$-0.14$0.06+142.5%

Revenue

EstBeatMiss
$507M$694M$880M$1.1B$1.3BQ4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$1.1B$1.2B+2.7%
Q4'25$1.1B$1.1B-3.7%
Q4'24 - $593M -

Market Data

ALNY Stock Snapshot

ALNY is currently trading at $314.40, giving ALNY a market cap of 41.54B and a P/E ratio of 953.4. Today's range spans $301.17–$318.44, with shares opening at $301.88 and moving up $5.92 (1.9%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 61/100.

Over the past year ALNY has traded between $205.87 and $495.55 - the current price is +52.7% off the 52-week low and -36.6% from the high.

Macro sensitivity explains some of ALNY's bearish setup (32/100, SELL) - at 41.54B in Healthcare market cap, interest rate shifts, currency moves, or commodity price changes can create fundamental headwinds that compound the technical deterioration. Sentiment: bullish (61/100). Price: $314.40 (in the lower half of its 52-week range). The current P/E ratio stands at 953.4. Annual range: $205.87–$495.55. The question for investors is whether the macro driver is transient or structural - because the answer determines whether this is a tradeable dip or a deeper re-rating.

When a large-cap Healthcare name with 41.54B in capitalization prints a SELL signal (32/100) alongside bullish news sentiment (61/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $314.40 (in the lower half of its 52-week range in the $205.87–$495.55 range), the structural support levels are where that sponsorship question gets answered.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…